Updated approaches for management of uterine fibroids. by Mas, Aymara et al.
© 2017 Mas et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php  
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
International Journal of Women’s Health 2017:9 607–617
International Journal of Women’s Health Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
607
R E V I E W
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/IJWH.S138982








1Reproductive Medicine Research 
Group, Institute of Health Research 
La Fe, University and Polytechnic 
Hospital La Fe, Valencia, Spain; 
2Research and Development 
Department, Igenomix Foundation, 
Valencia, Spain; 3Gynecology 
Department, University and 
Polytechnic Hospital La Fe, Valencia, 
Spain; 4Obstetrics and Gynecology 
Department, La Zarzuela Hospital, 
Madrid, Spain; 5Obstetrics and 
Gynecology Department, Universidad 
Francisco de Vitoria, Madrid, Spain
Abstract: Uterine anatomy and uterine fibroids (UFs) characteristics have been classically 
considered as almost a unique issue in gynecology and reproductive medicine. Nowadays, the 
management of UF pathology is undergoing an important evolution, with the patient’s quality of 
life being the most important aspect to consider. Accordingly, surgical techniques and aggressive 
treatments are reserved for only those cases with heavy symptomatology, while the clinical diag-
nostic based on size and number of UFs remains in a second plane in these situations. Moreover, 
the development of several noninvasive surgical techniques, especially the appearance of ulipristal 
acetate as a medical etiological treatment, has substantially changed the clinical indications. As 
a consequence, after almost 2 decades without relevant updates, it has been necessary to update 
the protocols for the management of UFs in the Spanish Society of Gynecology and Obstetrics 
twice. Accordingly, we believe that it is necessary to translate our experience to protocolize the 
medical care for patients with UFs, incorporating these new therapeutic options, and selecting 
the best treatment for them. We highlight the importance of achieving the patient’s goals and 
decisions by improving the clinical diagnosis for these type of pathologies, allowing enhanced 
personalized treatments, as well as the reduction of potential risks and unnecessary surgeries.
Keywords: uterine fibroids, UFs, selective progesterone receptor modulator, sPRM, ulipristal 
acetate, UPA
Introduction
To date, therapeutic options for long-term treatment of uterine fibroids (UFs) have been 
very limited, with surgery being the main medical treatment for 100 years, with large 
recurrences of tumors. In accordance with a statistical analysis, 200,000 hysterecto-
mies, 30,000 myomectomies, and thousands of selective uterine artery embolizations 
(UAEs) are performed annually in the USA to eliminate UFs, with a psychological 
load and economic costs to the patient and the health care system.1,2
Nowadays, the development of several noninvasive surgical techniques and the 
recent clinical introduction of selective progesterone receptor modulators (sPRMs) 
like ulipristal acetate (UPA) have implicated that some of these patients, who initially 
had surgical indication, may have an alternative and conservative treatment.3,4 As a 
consequence, the management of UF pathology is currently undergoing an important 
evolution, and after almost 2 decades without relevant updates, several scientific 
societies have found it necessary to actualize the protocols for the management of 
UFs. For instance, the Spanish Society of Gynecology and Obstetrics (SEGO) has 
done it twice.
The main issue to consider, regarding the diagnosis of UFs, is the general condition 
of the patient, considering the clinical symptoms not only in terms of health threat but 
also in terms of discomfort. As a consequence, we should look for the most efficient 
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treatment according to the patient’s preferences and clinical 
situation. Thereby, an accurate pelvic examination may give 
us the suspicion of these benign tumors.  As a consequence, 
the number, size, and location of UFs are essential for under-
standing the symptomatology and the evaluation of potential 
surgical techniques.
Although transvaginal ultrasound is the gold stan-
dard method for UF diagnosis in terms of accuracy and 
availability,5 it may be necessary to perform abdominal 
ultrasound and/or magnetic resonance imaging (MRI) to 
complete the study of these benign tumors.6 Additionally, 
hysteroscopy remains the most accurate method to diagnose 
and plan the specific treatment in submucosal UFs, and 
hemoglobin evaluation can also be a cheap and easy method 
to determine iron deficiency anemia in women with heavy 
menstrual bleeding.
In this review, we aim to offer a broad overview of UF 
management in our medical institutions, which includes clas-
sical surgery and noninvasive procedures, as well as medical 
treatment for 4 years. Consequently, we believe that it is 
convenient to share our knowledge to protocol the medical 
care for patients with UFs, incorporating these new therapeu-
tic options and selecting the best indications for them.
Current management options 
for UFs
Medical options
The first-line option for UFs is usually reserved to medical 
therapies because initially symptomatology is usually mild. 
We must discriminate between etiological and symptomatic 
treatment depending on whether the effect is directly on the 
UFs or only on their symptoms (Figure 1).
Classically, nonsteroidal anti-inflammatory drugs 
(NSAIDs) have been a regular solution for pain, in addition 
to hormones, either estroprogestins or progestogens, acting 
on the endometrium. In fact, the levonorgestrel intrauterine 
system (LNG-IUS) has become a success in gynecological 
therapy, and it is the reference for the progestin treatment.7 
Although it does not act directly on the UFs, it reduces men-
strual blood loss in women with this pathology. Therefore, 
it may be an excellent solution for mild and even severe 
bleeding when it is well tolerated.8,9
Tranexamic acid is a procoagulant drug that has also 
shown good results by reducing blood loss during menstrua-
tion, and it is very useful in women with UFs who have mild 
bleeding. It is only prescribed for 3 or 4 days per month and 
its dose may be adaptable according to each woman’s needs. 
It is usually well tolerated with few side effects.10,11
Also, gonadotropin-releasing hormone agonists (GnRHa) 
have been used to shrink UFs; however, they have been 
relegated because of their side effects such as hot flushes 
and bone loss.
Currently, with the incorporation of sPRMs like UPA, a new 
horizon has emerged in the management of fibroids.12,13
In our country, UPA is currently authorized by the 
Ministry of Health, Social Services and Equality, by the 
Spanish Agency of Medicines and Medical Devices and 
Health Products, and by the European Medicines Agency, 
for presurgical use and/or as a chronic treatment of UFs in 




















Figure 1 Surgical, nonsurgical, and medical therapy currently used for the management of UFs.
Abbreviations: GnRHa, gonadotropin-releasing hormone agonists; IUD, intrauterine device; MRgFUS, magnetic resonance-guided focused ultrasound surgery; NSAIDs, 
nonsteroidal anti-inflammatory drugs; RF, radiofrequency ablation; sPRMs, selective progesterone receptor modulators; UAE, uterine artery embolization; UFs, uterine fibroids.





suggests 3 months of treatment, 5 mg daily, alternating with 
two menses during four cycles as an intermittent treatment, 
or one or two cycles prior to surgery if the patient has ane-
mia. It allows the rapid control of the symptoms caused 
by these benign tumors, decreasing their volume by 50% 
after 12 months of treatment, in a similar manner as GnRH 
analogs, but presenting an excellent safety and tolerability 
profile.3,4,13–14 In addition, it produces amenorrhea in 80% 
of the patients, thus improving the clinical and analytical 
status of the patients. Therefore, it must be considered as 
a first-line treatment once symptomatic treatment is not 
effective.
For the past 4 years, our department has been providing 
UPA as a medical treatment for UFs. In our experience, 
UPA has shown results similar to those in the literature, 
although the mean reduction of volume in our results has 
been around 30%. Nevertheless, this measure must be care-
fully considered, because it correlates to 10% in diameter 
and may discourage the clinician expectations (Figure 2). 
On the other side, an excellent control of bleeding, caus-
ing amenorrhea, in most of the patients has been achieved. 
Tolerance and  safety have been also good, with few patient 
withdrawals due to side effects, and no severe adverse effects. 
Likewise, surgery, when necessary, is not compromised after 
treatment with UPA.
Regarding long-term treatment, UPA is planned in four 
cycles; however, for patients with mild symptoms, two 
cycles of 3 months may be sufficient. Thus, the indication 
of intermittent treatment with UPA should comprise two 
steps: the first one regarding the stabilization and recovery 
of anemia and the second one related to maintenance.15–17 
Finally, once the patient is stabilized after two or four cycles 
and recovered from the general condition, we can reevalu-
ate the situation, considering several options. Occasionally, 
we may start a follow-up without medication if condi-
tions have improved significantly. However, in the cases 
where a relapse of the symptomatology is predictable, we 
should plan more treatments. A combination with another 
treatment method, like LNG-IUS, is recommended after 
finishing UPA.
Surgical options
Surgical interventions still represent the main strategies 
for UF management, with hysterectomy, laparoscopic 
myomectomy, and hysteroscopic myomectomy being the 
most widely used (Figure 1).18 Nevertheless, all things 
considered, the surgeon’s experience is the key factor to 
contemplate when we plan the surgical approach.
Hysterectomy
This option is a radical and definitive treatment for UFs, 
particularly for women who do not wish to conceive and/or 
women aged above 40–50 years.19 We must point out that 















































Figure 2 Diagram showing the relationship and the expected changes in uterine fibroids’ diameter corresponding to the changes in volume (A), both in percentage (B) and 
fixed values (C). As volume is proportional to the radius to the cube, significant changes in volume mean smaller differences in radius or diameter.





with big myomas, and it is the cheapest and less invasive one. 
Supracervical hysterectomy is indicated if surgical compli-
cations are present, but as there are no differences in sexual 
and urinary function, it is our thought that total hysterectomy 
should be preferred.20–22
Abdominal myomectomy (laparoscopy or 
laparotomy)
Excision of the fibroids and anatomical reconstruction of the 
uterus have been for decades the only technique available 
for women who wanted to retain their uterus.23–31 Depending 
on the number, size, and location of fibroids, we will choose 
the optimal surgical approach.
Hysteroscopic myomectomy
Hysteroscopy is the elective method to remove submucous 
UFs by using minimally invasive surgical procedures.32–36 
Currently, the use of new devices (myosure, truclear, and 
so on) to perform hysteroscopic procedures in the outpatient 
setting has completely changed the clinical approach. But, 
it is important to balance the expectation of success and 
the length of surgery, and if it is not adequate, we should 
perform a classic surgical intervention with resectoscope. 
Moreover, we should always try to enucleate the UFs of their 
pseudocapsules before their fragmentation and elimination. 
This method could give us better fertility results after surgery, 
reaching rates of 45% and reducing complications.32,37–40
Nonsurgical alternatives: UAE and 
magnetic resonance-guided focused 
ultrasound surgery
The alternatives to surgical interventions are shown in 
Figure 1.
Uterine artery embolization
Embolization of uterine arteries is a safe and minimally 
invasive technique, with similar results in terms of satisfac-
tion compared with the surgical procedures (both hysterec-
tomy and myomectomy). A lower rate of minor complications 
have been reported, although the probability of the need for a 
new surgical procedure to be done in 2–5 years is increased 
compared to surgical procedures including myomectomy and 
hysterectomy (15%–32% vs 7%). Besides, the fact that ovar-
ian reserve and healthy myometrium may be compromised 
still discourages its use prior to pregnancy.41 From our point 
of view, UAE is indicated for patients wishing to preserve 
their uterus, because in our experience, the results are similar 
to surgery in terms of discomfort and pain, and much worse 
than hysterectomy according to the rate of reinterventions 
in the long term.42–44
Fibroid ablation
The term ablation refers to tissue destruction with concen-
trated energy. It is also called myolisis, and there are different 
sources of energy, such as ultrasound, radiofrequency (RF), 
and laser. Initially, surgical procedures were required, but 
nowadays ultrasound or MRI selects the point where the 
energy must be guided.6 Ultrasound-guided puncture with RF 
or/and high-frequency magnetic resonance-guided focused 
ultrasound surgery (MRgFUS) are minimally invasive 
alternatives that decrease menstrual bleeding and the size of 
UFs.45 However, fertility seems not to be compromised with 
these techniques and surgical intervention may be needed at 
a higher rate than UAE. According to our experience, both 
procedures are more suitable for UFs with a component of 
pain or compression.
Algorithm for the management 
of UFs
Basis of management
There is a great variability among the patients with UFs. Differ-
ences in age, severity of symptoms, and characteristics of these 
benign tumors make it difficult to suggest a general rule of treat-
ment, and the individual assessment of each case is necessary. 
Nevertheless, we may clarify some general issues that should 
always be considered in the management.1,46
While several classifications can be found in the 
literature,40,47 the International Federation of Gynecology 
and Obstetrics (FIGO) classification is the most employed 
nowadays because it offers a broad fibroid distribution 
map.48 FIGO employs a nine-point numerical system to 
describe the location of UFs in relation to the endometrium 
and the serosal surface. Pedunculated UFs localized in the 
submucosa, extending inside the uterine cavity, are clas-
sified as type 0, while type 1 and type 2 are submucosal 
UFs that have 50% of intramural location. Type 3 UFs 
are completely located intramural with contact to the endo-
metrium, whereas type 4 UFs are intramural lying entirely 
in the myometrium. Types 5–6 represent subserosal UFs 
with 50% of intramural location and type 7 is attached 
to the serosa by a stalk (pedunculated). Type 8 covers all 
other UFs not related to the myometrium such as cervical 
or parasitic lesions (Figure 3).
Fibroids are benign tumors and they often grow during 
fertile age, until the woman reaches menopause, which 
causes sexual hormone depletion. Thus, menopause means 





a “spontaneous cure,” avoiding the need for treatment with 
few exceptions.
Good quality of life and patient satisfaction must be our 
goals in the management of fibroids. Therefore, the number 
of interventions should be minimized, and if radical treat-
ment is needed (hysterectomy), it is better to perform it as 
soon as possible. Treatment should be efficient with the 
maximum efficacy and the minimum risk and cost. It should 
also be indicated proportionally according to the severity of 
symptoms, and may be increased gradually. We should be 
as non-aggressive and noninvasive as possible. For instance, 
if a symptomatic medical treatment is effective enough we 
should maintain it.
In addition, it is not necessary to emphasize that asymp-
tomatic UFs do not require treatment regardless of their size. 
However, the bigger the size, the more probable it is that they 
cause symptomatology. Nevertheless, follow-up is required, 
and 6 months seems reasonable, extending it to 1 year if there 
is no growth detected. Finally, fibroids that have not been 
modified during a 1-year period after menopause will not 
require further control unless symptoms appear.
The probability of malignancy is extremely rare. Although 
it is not completely clear, the current belief is that UFs do 
not change to leiomyosarcomas, but the latter are malignant 
from the beginning.49,50 The incidence of leiomyosarcoma is 
extremely low, and it has been estimated at 1:400 (0.23%) in 
women who undergo surgery for UFs.51 However, in meno-
pausal women, the probability of malignancy increases in 
growing fibroids, reaching 1% of hysterectomy specimens 
in women in their 60s.49,50 Then, we should not suspect for 
leiomyosarcoma unless ultrasound or clinical characteristics 
suggest it. In these specific cases, MRI may be helpful, 
although there is no reliable diagnostic test at this moment 
that differentiates between leiomyosarcoma and UFs.52
In brief, it is important to design a global plan of manage-
ment considering the whole reproductive age. We must do 
an initial assessment of the patient, considering the medical 
condition and symptomatology, the characteristics of the 
uterus and UFs, and the patient’s desires, especially preg-
nancy, as well as the patient age and proximity to menopause. 
We must also try to foresee the evolution of the pathology, 
pondering the odds of different possible developments, as 
well as the available treatments balancing benefits, risks, and 
probabilities of success, and communicate all this informa-
tion to the patient. Then, we will choose the more efficient 
treatment, according to her needs, desires, and decisions.
Stages of management
Patients with symptomatic UFs may initially be divided into 
two big groups, in terms of objectives, symptomatology, and 
age. Most of them demand treatment during the perimeno-
pause because of symptomatic UFs (pain, bleeding, bulky 
effect, and so on) that affect their quality of life. There are 
also a relevant number of patients, generally at a younger 
age, consulting for infertility, which requires specific 
management. However, it should be remembered that both 
groups can often overlap and participate in both situations.
The two stages of management are: 1) The first question 
in the management of symptomatic UFs should consider if 
there is a hysteroscopic solution. When symptomatology is a 
consequence of a UF accessible by hysteroscopic approach, 





























Figure 3 The International Federation of Gynecology and Obstetrics classification system for uterine fibroids.





of other characteristics of the patient.53 Sometimes, despite 
the persistence of other subserosal or intramural fibroids, both 
in perimenopausal and potentially pregnant patients, a partial 
solution of removing one or several submucosal fibroids, and 
cleaning the cavity, may solve the problem.54,55 Nonetheless, 
depending on the difficulty of the case, a two-stage approach 
may be considered.
In brief, optimal diagnosis is essential in hysteroscopy, 
and the classification system (STEP-w) for hysteroscopic 
myomectomies, based on the degree of technical difficulty 
in carrying out the procedure, should be recommended for 
the most suitable course of action in each situation.56 For 
example, in simple cases, we may perform endometrial 
preparation with progestogens or oral contraceptives to 
facilitate intervention. Conversely, in complicated cases, 
we should plan a prior treatment with one or two cycles of 
UPA before the surgery. For example, in those situations, 
where there is a poor health condition and especially when 
the patient is anemic, we will proceed to administer a UPA 
cycle to delay surgery and recover hemoglobin levels, as 
well as the patient’s condition. In these cases, hysteroscopy 
may be performed on the last days of treatment or even after 
the first menstruation. In our experience, around 2 weeks 
after finishing the treatment, menstruation is avoided and an 
adequate surgical technique is enabled.55,57
2) When the hysteroscopic resection is not possible or 
adequate, we have a wide range of options for treatment, 
and we should adopt them according to the characteristics 
and preferences of the patients. First, we have to identify the 
patient’s profile regarding whether her problem is symptoma-
tology or infertility. It is also relevant to consider the age and 
proximity to menopause, as well as the desire for pregnancy, 
and the preferences of the patient.
We highlight the importance of a comprehensive diagnosis 
considering specific factors and circumstances such as num-
ber, location, and type of UFs, associated symptomatology, 
quality of life, and health condition, among others. Consider-
ing all these premises, we have established an algorithm for 
each group of patient profile, either patients with symptoma-
tology and patients who do not wish to be pregnant or those 
whose problem is mainly infertility. These two groups will 
include most of the patients in a general perspective, although 
we still emphasize the need of personal counseling.
Medical algorithm according to the 
patient’s profile
Perimenopausal women without gestational desire
Symptomatology in this group of women may be classified 
into mild or moderate–severe. It should be noted that in real 
patients, there is an endless number of situations between 
being asymptomatic and having a severe symptomatology.
Then, in mild conditions, many fibroids that had been 
asymptomatic start producing mild bleeding or pain. In most 
cases, symptomatic treatment is enough to maintain an adequate 
quality of life. If the main symptom is hypermenorrhea, drugs 
such as tranexamic acid,58 progestogens (oral or LNG-IUS),59–61 
or oral contraceptives (estroprogestogens) are eligible.62,63 If 
the patient refers mainly pain, NSAIDs should be prescribed, 
which could also have a limited effect on bleeding.64–66 Not-
withstanding, the assessment of the patient, at least every 6 
months, following evaluation and satisfaction with the treat-
ment, should be recommended (Figure 4).
However, moderate–severe conditions are considered 
if symptomatic treatments are not enough to provide an 
adequate quality of life, and surgery has been classically 
the preferred solution. Nowadays, we can count on different 
options that provide good results and make it not necessary 
to remove the uterus.
Age and proximity to menopause are the most important 
factors to consider. It is also important to know the opinion 
of the patient about losing her uterus. For example, when a 
patient is 48 years or older, we estimate as a general rule that 
medical treatment will be sufficient to reach menopause, and 
UPA in intermittent cycles will be our first option, relegating 
hysterectomy and other methods to a second option. In fact, 
health economic-related studies indicate that the economic 
impact is lower with UPA treatment than hysterectomy at 
4 years after diagnosis of UFs.67
Nevertheless, bulky effect and dysfunction of neigh-
boring organs may modify this general approach. When 
the patient without gestational desire is younger than 
42–44 years, the first option indicated would be hysterec-
tomy. Hysterectomy provides a radical and definitive therapy 
because a long period of time is expected until menopause. 
Therefore, the risk and invasiveness seem justified. We 
should also remark that myomectomy is not indicated in 
perimenopausal woman who do not want to get pregnant 
because it is often more bloody and riskier than hysterectomy, 
and the recurrence of UFs and symptoms can still occur. 
Alternatively, if the patient wants to conserve her uterus, 
UAE or UF ablation (with MRgFUS or RF) may be the good 
approach and intermittent medical treatment with UPA may 
be a good option for willing patients aware of the duration 
of the treatment (Figure 4).
In summary, it is taken for granted that all these treatment 
options are assessed with the patient, informing the pros and 
cons and pondering her desires. Finally, the patient’s decision 
and expectations should determine our attitude.





Women with gestational desire
We have to differentiate those patients who wish to gestate 
immediately from those who do not wish to gestate in the 
short-term, but want to in the future. We should also add 
the group of patients already diagnosed with infertility where 
UFs are the etiological condition (Figure 4).
Regarding patients with short-term desire of gestation, 
we should clearly differentiate those who may try to get 
pregnant despite the fibroids, and those who should undergo 
a treatment before becoming pregnant. Approximately, half 
of the UFs will not cause problems in the gestation, but on 
the other hand, a third could induce abortions and premature 
births.68 In both cases, it is not easy to correctly assess these 
patients, although compromise of the endometrial cavity and 
the location of fibroids are essential to define. As a general 
rule, submucous UFs (0, 1, and 2) should be operated on by 
hysteroscopy. However, type 4 intramural UFs larger than 
5 cm and types 5 and 6 larger than 6–7 cm should be treated 
(Figure 4).
In general, we still consider myomectomy as the stan-
dard treatment in this group, where the patient may gestate 
between 4 and 6 months after surgery, or even earlier.23,69 We 
also prescribe one or two cycles of UPA presurgically only 
in case of anemia because of hypermenorrhea. In this case, 
the consistency of the UF is usually softer after UPA, but the 
surgical plane on the pseudocapsule is preserved, so this does 
not hinder treatment and laparoscopic surgery is adequate.
We obviously reject hysterectomy as an option for treat-
ment, but it should be noted and included in the informed 
consent as an unexpected consequence if a myomectomy is 
to be performed. However, the risk is low and should never 
exceed 2%–3% of myomectomies.
We do not recommend UAE either, because of potential 
commitment of the ovarian reserve or healthy myometrium. 
And, only in cases of a single, symptomatic fibroid with a 
difficult surgical access, ablation (either MRgFUS or RF) 
may be indicated, considering that gestation does not seem 
to be affected and UF growth stops.
However, the treatment with one or two UPA cycles 
could be the solution in patients with type 3 myomas or 
those where a slight decrease in size may improve cavity 
condition. In these cases, the volume reduction of the UF 
may achieve a regular endometrial cavity free of UF. Patients 
could then safely gestate after the second, and probably the 
first menstruation. The effects in gestation seem to be ben-
eficial because gestation appears to inhibit fibroids’ growth 
through apoptosis that occurred during the treatment period. 
No adverse teratogenic effect has been reported.70,71
UPA treatment should be a valid alternative also in poly-
myomatous uterus and those presenting myometrial scars, 
Figure 4 Medical algorithm for the management of UFs according to the patient’s profile.
Abbreviations: LNG-IUS, levonorgestrel intrauterine system; MRgFUS, magnetic resonance-guided focused ultrasound surgery; NSAID, nonsteroidal anti-inflammatory 
























































































with uncertain surgical outcome. In any case, the situation 
could be reassessed after treatment, evaluating the effect on 
UFs and the influence on the endometrial cavity.
When the desire of pregnancy is deferred over time, 
it is recommended to delay the intervention until the 
moment when the patient is willing to gestate. Recurrence 
of fibroids is frequent and surgery becomes more difficult 
each time, worsening the prognosis and increasing the 
risks of hysterectomy. Therefore, we should follow-up and 
assess the growth of UFs. If the patient presents symptoms, 
symptomatic treatment (progestogens and tranexamic acid) 
or UPA is recommended. However, myomectomy should be 
indicated if the patient does not have a good quality of life. 
UPA administration may be considered in asymptomatic 
patients as secondary prevention, especially in young women 
who do not want to get pregnant in 5 or 10 years. UF growth 
would stop and possibly the size would decrease, and this 
will allow delaying of a potential surgery in order to prevent 
UF complications during pregnancy (Figure 4).
Discussion
UFs represent a prevalent problem with different degrees 
of effect on patients, involving a large personal and social 
cost.2,18,72 In fact, a range of possible patient states are dis-
played, from those who are asymptomatic to others with 
severe symptoms that can produce anemia and serious 
complications. On the other hand, the fact that it is a benign 
pathology with several options of treatment has contributed 
to underestimating the attention of this pathology.
Classically, the attention of UFs has focused on their 
study and characteristics by guiding the treatment, often 
without going deeply into the specific needs and preferences 
of the patient.
The treatment of these benign tumors has been eminently 
surgical. However, UFs with mild symptoms could be man-
aged with drugs aimed to attend to the specific symptom, 
usually bleeding or pain.60–62,65–67,73
Recently, the huge information available as well as the 
demand for clinical results contributes to a greater power 
of decision from patients, resulting in the search for less-
invasive and costly methods. Moreover, surgical procedures 
have also evolved, being less aggressive and having a better 
recovery.3,23–31,33–37 Finally, alternative methods of inter-
ventional radiology such as UAE and ablation have been 
developed, with good results.6,45
Two decades ago, with the emergence of GnRH ana-
logs, a curtain of hope was opened, with a treatment that 
finally acted directly on UFs. Nevertheless, the side effects 
and the briefness of the medical effect resulted in them 
being abandoned progressively.74,75 Recently, a new drug 
has appeared, with a direct effect on UFs and barely any 
side effects, allowing a long-term treatment. UPA treat-
ment also causes amenorrhea as a side effect in a high 
percentage of patients, by monitoring the bleeding, which 
is the most frequent symptom. In summary, this is a real 
milestone in the management of UF pathology, which may 
allow patients to be treated by avoiding surgery in many 
cases.4,12–17
As a consequence, after almost 2 decades without relevant 
updates, it is necessary to update the protocols for the man-
agement of UFs. In fact, the SEGO has changed its protocol 
twice, and the Canadian and other societies, have reflected 
their interest in several articles.76,77
However, it is crucial to transfer the experience to the 
gynecologist, who will handle the greatest number of cases, 
given the characteristics of the pathology. Frequently, it is 
difficult to introduce new ways of acting in deeply rooted 
habits. For this reason, we believe that it is important to estab-
lish specific protocols that facilitate the implementation of the 
new therapies. Therefore, it is necessary to establish several 
profiles or groups of patients with common characteristics, 
arranging for a couple of treatment possibilities and creating 
a putative algorithm.
It is easy to see that the clear majority of patients are 
from their 40s to the early 50s. They are usually women with 
reproductive desire fulfilled and whose main symptoms are 
bleeding and pain. Alongside them there is another group, a 
decade younger, where the main concern is infertility, gener-
ally with little incidence of symptomatology.23 Addressing 
the problem requires different points of view. Nevertheless, 
in all cases, a detailed diagnosis with a meticulous descrip-
tion of UFs and their topography is crucial.
We believe that surgical treatment remains an excellent 
option. However, in those cases where the UFs are amenable 
to hysteroscopy, other considerations should be taken into 
account. In addition, the use of UPA as an adjunctive treat-
ment prior to hysteroscopy has been shown to be beneficial 
in the reduction of UFs and recovery of the patient prior 
to surgery.55,57 It also modifies the approach of fibroids 
with greater surgical complexity, by making the interven-
tion easier.4,13–14,17 Nevertheless, in patients where the 
hysteroscopic solution is not possible, we must consider the 
different profiles mentioned above. Additionally, it is impor-
tant to consider the woman’s fertile life so that we can project 
the most probable scenarios in her pathology. In that way, 
doctors could recommend the solution that is considered more 





efficient, minimizing on the one hand the surgical procedures 
and medication regarding a good quality of life.
On the other hand, although hysterectomy remains a 
valid option for those patients who want a definitive solution, 
we believe that, in those patients over 48 years of age, and 
perhaps a little younger, a medical treatment should first be 
offered. In fact, UPA treatment could allow achievement of 
the menopause by preserving the patient’s quality of life in 
the least expensive way in economic and social terms.14,16–17 
We chose this age as a cut-off point because economic studies 
seem to reflect that UPA treatment is cost-effective at this 
period of time.14,67 Thus, a large percentage of women would 
reach menopause by that age.
Myomectomy in patients without gestational desire 
should be discouraged from our point of view, because the 
intervention is more aggressive than hysterectomy, and in 
the case of wanting to preserve the uterus, the UAE method 
is less invasive and more reliable.41–44 Conversely, among the 
patients with gestational desire, we must differentiate those 
who want to get pregnant immediately, from those who want 
to postpone pregnancy for several years. In the latter, we 
will try to avoid surgery until the moment when they want 
to gestate, to reduce the number of surgeries and recurrences 
of UFs. Therefore, although the success of UPA treatment as 
a secondary prevention of UF pathology is still unknown, the 
fact that it stops the UF growth over 6 months at least may 
allow delaying of the surgical techniques.70,71
When the patient has immediate gestational desire, we 
must carefully evaluate if she will be able to become preg-
nant, or if she needs a prior treatment. Classic myomectomy 
remains the most commonly used method,23–25 although lap-
aroscopy and laparotomy remain as effective tools, especially 
in cases of multiple fibroids.27–31 In these cases, 6 months of 
waiting time between surgery and gestation should be suf-
ficient, although it can probably be established in an even 
shorter period.
Experience and accuracy in diagnosis are crucial in the 
decision. We consider that the main complications in the 
second and third trimester regarding the fetal pathology are 
due to the presence of fibroids and triggering of maternal 
complications which can make a hysterectomy necessary.68 
Nowadays, we do not have reliable methods to discern which 
fibroids will grow, but we know that about two thirds will 
remain stable. However, in borderline cases, the UPA treat-
ment allows an opportunity to reassess patients after one 
or two courses. If it has been effective and there has been 
sufficient reduction, it may allow cases initially intended for 
surgery to attempt gestation without further treatment.70,71 
We believe that after two regimens, once the treatment is 
finished, the safety for gestation is maximum. Additionally, 
RF ablation and MRgFUS do not appear to affect fertility, 
and are also good methods for UFs with difficult surgical 
access.6,45
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